Vaxart Announces Leadership Changes and Executive Compensation Updates
Ticker: VXRT · Form: 8-K · Filed: Feb 29, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation
TL;DR
**Vaxart just shook up its leadership and compensation, keep an eye on what's next!**
AI Summary
Vaxart, Inc. filed an 8-K on February 29, 2024, reporting events that occurred on February 27, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. This indicates changes in the company's leadership and executive compensation structure.
Why It Matters
Changes in executive leadership and compensation can signal strategic shifts or financial health adjustments within a company, impacting investor confidence and future direction.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company strategy and performance, but the specific details are not provided in this excerpt.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Delaware (company) — State of incorporation
- February 27, 2024 (date) — Date of earliest event reported
- February 29, 2024 (date) — Filing date
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 27, 2024.
What is the primary focus of the 'ITEM INFORMATION' sections in this 8-K?
The primary focus of the 'ITEM INFORMATION' sections is the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on February 29, 2024.
What is Vaxart, Inc.'s state of incorporation?
Vaxart, Inc.'s state of incorporation is Delaware.
What is Vaxart, Inc.'s SEC File Number?
Vaxart, Inc.'s SEC File Number is 001-35285.
Filing Stats: 764 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-02-29 16:30:17
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20240227_8k.htm (8-K) — 29KB
- ex_631955.htm (EX-10.1) — 153KB
- ex_631956.htm (EX-10.2) — 67KB
- ex_631957.htm (EX-10.3) — 82KB
- 0001437749-24-006109.txt ( ) — 524KB
- vxrt-20240227.xsd (EX-101.SCH) — 3KB
- vxrt-20240227_def.xml (EX-101.DEF) — 11KB
- vxrt-20240227_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240227_pre.xml (EX-101.PRE) — 11KB
- vxrt20240227_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 27, 2024, the Board of Directors (the "Board") of Vaxart, Inc. (the "Company") adopted the Vaxart, Inc. 2024 Inducement Award Plan (the "2024 Inducement Plan"). The 2024 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and will be administered by the Compensation Committee of the Board or the independent members of the Board. The Board reserved 3,000,000 shares of the Company's common stock for issuance under the 2024 Inducement Plan, subject to adjustment as provided in the plan document. The terms of the 2024 Inducement Plan are substantially similar to the terms of the Company's 2019 Equity Incentive Plan, with the exception that incentive stock options may not be issued under the 2024 Inducement Plan and equity awards under the 2024 Inducement Plan (including nonqualified stock options, restricted stock, restricted stock units, and other stock-based awards) may be issued only to an employee who is commencing employment with the Company or any subsidiary or who is being rehired following a bona fide interruption of employment by the Company or any subsidiary, in either case if he or she is granted such award in connection with his or her commencement of employment and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The Board also adopted a form of restricted stock unit award grant notice and award agreement (the "Inducement RSU Grant Package") and a form of stock option grant notice and stock option agreement (the "Inducement Stock Option Grant Package") for use under the 2024 Inducement Plan. The foregoing description of the 2024 Inducement Plan, the Inducement RSU Grant Package, and the Inducement Stock Option Grant Package does not purport to be complete and is qualified in
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Vaxart, Inc. 2024 Inducement Award Plan. 10.2 Form of Restricted Stock Unit Award Grant Notice and Award Agreement. 10.3 Form of Stock Option Grant Notice and Stock Option Agreement. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaxart, Inc. Dated: February 29, 2024 By: /s/ MICHAEL J. FINNEY Michael J. Finney, Ph.D. Interim Chief Executive Officer